Brian J. Druker
Oregon Health & Science University Knight Cancer Institute
Portland
Oregon
USA
Name/email consistency: high
- Perspectives on the development of imatinib and the future of cancer research. Druker, B.J. Nat. Med. (2009)
- Translation of the Philadelphia chromosome into therapy for CML. Druker, B.J. Blood (2008)
- Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. Druker, B.J., Guilhot, F., O'Brien, S.G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M.W., Silver, R.T., Goldman, J.M., Stone, R.M., Cervantes, F., Hochhaus, A., Powell, B.L., Gabrilove, J.L., Rousselot, P., Reiffers, J., Cornelissen, J.J., Hughes, T., Agis, H., Fischer, T., Verhoef, G., Shepherd, J., Saglio, G., Gratwohl, A., Nielsen, J.L., Radich, J.P., Simonsson, B., Taylor, K., Baccarani, M., So, C., Letvak, L., Larson, R.A. N. Engl. J. Med. (2006)
- Imatinib: paradigm or anomaly?. Druker, B.J. Cell. Cycle (2004)
- Molecularly targeted therapy: have the floodgates opened?. Druker, B.J. Oncologist (2004)
- Practical management of patients with chronic myeloid leukemia receiving imatinib. Deininger, M.W., O'Brien, S.G., Ford, J.M., Druker, B.J. J. Clin. Oncol. (2003)
- Imatinib mesylate in the treatment of chronic myeloid leukaemia. Druker, B.J. Expert. Opin. Pharmacother (2003)
- David A. Karnofsky Award lecture. Imatinib as a paradigm of targeted therapies. Druker, B.J. J. Clin. Oncol. (2003)
- STI571 (Gleevec) as a paradigm for cancer therapy. Druker, B.J. Trends. Mol. Med (2002)
- Perspectives on the development of a molecularly targeted agent. Druker, B.J. Cancer. Cell (2002)
- Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML. Druker, B.J. Oncogene (2002)
- Imatinib and chronic myeloid leukemia: validating the promise of molecularly targeted therapy. Druker, B.J. Eur. J. Cancer (2002)
- Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. Druker, B.J., Talpaz, M., Resta, D.J., Peng, B., Buchdunger, E., Ford, J.M., Lydon, N.B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., Sawyers, C.L. N. Engl. J. Med. (2001)
- Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. Druker, B.J., Sawyers, C.L., Kantarjian, H., Resta, D.J., Reese, S.F., Ford, J.M., Capdeville, R., Talpaz, M. N. Engl. J. Med. (2001)
- Chronic myeloid leukemia. Sceptical scientists. Druker, B.J. Lancet (2001)
- The role of the tyrosine kinase inhibitor STI571 in the treatment of cancer. O'Dwyer, M.E., Druker, B.J. Curr. Cancer. Drug. Targets (2001)